Back to search

France· FR:65732820

ZONISAMIDE NEURAXPHARM 25 mg, comprimé sécable

A zonisamide product containing zonisamide, registered in France by NEURAXPHARM FRANCE, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC N03AX15

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedZONISAMIDE NEURAXPHARM 25 mg, comprim…ATCN03AX15REGISTER NO.FR:65732820PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Zonisamide is registered in 18 of 19 countries.

Countries holding a registration under ATC N03AX15 (zonisamide), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 11 of them publish a price we can compare per daily dose

Zonisamide · ATC N03AX15

18 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of zonisamide costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), the median price runs from $0.78 in United States to $10.28 in Switzerland — a ×13 gap.

  • France: $1.20 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Zonisamide · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

  • CH Switzerland$10.28
  • IT Italy$2.90
  • FR France$1.20
  • US United States$0.78 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
ZONISAMIDE
Manufacturer
NEURAXPHARM FRANCE
Country
France (FR)
ATC code
N03AX15
ATC class
Zonisamide
Defined daily dose
0.4 g, O
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930258415
    plaquette(s) PVC aluminium de 14 comprimé(s)
    EUR 3.8

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

239 interactions on record for zonisamide.

Graded by severity as the source publishes them — 43 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Zonisamide · interactions on record

239 records

  • 43 severe
  • 105 moderate
  • 66 info

Most severe, free to view

  • DicycloverineA03AA07severe
  • PropanthelineA03AB05severe
  • MepenzolateA03AB12severe
  • TrospiumA03AB20severe

25 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Zonisamide in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All zonisamide products

Authorised across Europe · EMA

The same active substance is authorised in 24 EEA countries. Names it is sold under:

  • Austria · Zonisamid Aristo
  • Bulgaria · Зокап
  • Czechia · Ersittin, Zonisamid Sandoz
  • Germany · Zonisamid 1 A Pharma, Zonisamid Accord
  • Denmark · Zonisamid Desitin, Zonisamid Glenmark
  • Estonia · Zonisamide Sandoz
  • Spain · Nyzol, Zonesme
  • Finland · Zonisamide Desitin
  • United Kingdom (Northern Ireland) · Desizon, Zonisamide Accord
  • Croatia · Zocap
  • Ireland · Zonisamide Desitin, Zonisamide Rowex
  • Iceland · Zonegran, Zonisamide Viatris
  • Italy · Zonisamide Doc Generici, Zonisamide Sandoz
  • Liechtenstein · Zonegran, Zonisamide Viatris
  • Lithuania · Zonisamide Sandoz
  • Malta · Zonisamide Doc Generici
  • Netherlands · Zonisamide Indoco, Zonisamide Sandoz
  • Norway · Zonegran, Zonisamid Desitin
  • Poland · Zonisamidum Neuraxpharm
  • Portugal · Zonisamida Aristo, Zonisamida Generis
  • Romania · Zocap, Zonisamidă Desitin
  • Sweden · Zonisamide 1a Farma
  • Slovenia · Zocap, Zonisamid Sandoz
  • Slovakia · Zonisamide Neuraxpharm

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e67270c1-24bb-4d79-904a-e2d3a8dd6fe2
GET /v1/drugs/e67270c1-24bb-4d79-904a-e2d3a8dd6fe2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "65732820",
  "date_amm": "2022-07-27",
  "type_amm": "Procédure décentralisée",
  "numero_ue": null,
  "substance": "ZONISAMIDE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "comprimé sécable",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about zonisamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.